Elegen, a leader in next-generation cell-free DNA production, has announced the early access launch of its Gen II DNA Production Platform. This platform features the world’s first directed split-pool microfluidic synthesizer, enhancing Elegen’s proprietary cell-free cloning technology which eliminates the need for plasmids. The platform is engineered to facilitate the rapid production of longer, higher quality, complex DNA at costs lower than those associated with currently available low-quality gene fragments.

The Gen II Cell-Free DNA Synthesizer Platform represents the first high-throughput DNA factory tailored for the AI era of genetic medicine and synthetic biology. By replacing outdated, bulky synthesizers and removing bacteria from the cloning process, Elegen significantly reduces labor costs and capital expenditures. This compact design also reduces the footprint of high-volume DNA production by more than tenfold, resulting in unmatched manufacturing agility. Elegen's offerings include linear DNA, up to 7 kb with high complexity; 19 kb plasmids with up to 15 kb inserts; and linear DNA with up to 130-nucleotide poly(A) tails, ready for in vitro transcription, all shipped globally from their Menlo Park, California facility.

“With Gen II, Elegen has created the first, high-throughput DNA factory designed for the AI era of genetic medicine and synthetic biology,” stated Matt Hill, Ph.D., Founder and CEO of Elegen. He emphasized that a critical feature of the platform is its ability to be deployed on-premises, allowing for ultra-fast turnaround of large numbers of clonal sequences for applications like personalized cancer therapies that demand rapid, high-volume production. “Our high-throughput DNA production system will allow us to support a variety of clients from rapid design-build-test-learn workflows all the way through to the clinic.”

The Gen II Early Access Program is now available to select partners and collaborators looking to speed up their processes without sacrificing quality or cost. Organizations interested in learning more can visit elegenbio.com/Gen2.